Steven Grant

Title: The Innovative Contributions of Steven Grant in Antibody Research

Introduction

Steven Grant, based in Cambridge, GB, is a renowned inventor with a remarkable portfolio that includes 20 patents. His work predominantly focuses on innovative advancements in antibody research, particularly in understanding and targeting specific receptors related to various diseases.

Latest Patents

Among his latest patents, Steven has developed anti-P2X7 receptor antibodies and fragments thereof. This invention pertains to an antigen binding site defined by a general formula that allows for effective binding to a P2X receptor. Additionally, he has created antibody polypeptides that antagonize CD40L, specifically designed to bind to human CD40L without activating platelets. These polypeptides hold potential for therapeutic applications in treating diseases linked to CD40L activation, such as graft-related diseases and autoimmune disorders. Notably, these antibody polypeptides can be modified to increase their half-life, enabling them to be dual-specific reagents that also bind to human serum albumin or other antigens.

Career Highlights

Steven has held significant positions in prominent companies, including Domantis Limited and Bristol-Myers Squibb Company. His extensive experience in these organizations has contributed to his expertise and success in the field of antibody research and development.

Collaborations

Throughout his career, Steven Grant has collaborated with distinguished colleagues, such as Anish Suri and Suzanne J. Suchard. Their collective efforts have undoubtedly advanced the landscape of innovative treatments in immunology.

Conclusion

In conclusion, Steven Grant's contributions to antibody innovation are pivotal in modern medicine. With a strong focus on designing antibodies that address critical health challenges, his work exemplifies the intersection of science and innovation, paving the way for future treatments and therapies.